Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
暂无分享,去创建一个
Björn Olsson | György Horvath | B. Olsson | K. Partheen | G. Horvath | K. Sundfeldt | Karin Sundfeldt | Karolina Partheen | Kristina Levan | Ulla Delle | Lovisa Österberg | K. Levan | L. Österberg | U. Delle
[1] Y. Wan,et al. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. , 2008, Cancer letters.
[2] I. Nagata,et al. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] Ian H. Witten,et al. Data mining in bioinformatics using Weka , 2004, Bioinform..
[4] J. Staaf,et al. High-Resolution Genomic Profiling of Carboplatin Resistance in Early-Stage Epithelial Ovarian Carcinoma , 2009, Cytogenetic and Genome Research.
[5] J. Inazawa,et al. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] A. Eastman,et al. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. , 1990, Biochemical pharmacology.
[7] J. Rowley,et al. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[8] E. Nogales,et al. Structure of the alpha beta tubulin dimer by electron crystallography. , 1998, Nature.
[9] Jane Fridlyand,et al. Bioinformatics Original Paper a Comparison Study: Applying Segmentation to Array Cgh Data for Downstream Analyses , 2022 .
[10] J C Reed,et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.
[11] R. Burger,et al. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. , 2005, Cancer research.
[12] S. Minkin,et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. , 2005, Neoplasia.
[13] Hanna Göransson,et al. Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia—A comparative study of four differently designed, high resolution microarray platforms , 2008, Genes, chromosomes & cancer.
[14] Johan Staaf,et al. High‐resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization , 2007, Genes, chromosomes & cancer.
[15] C A SALVATORE,et al. [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.
[16] A. Godwin,et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[17] Q. Zhan,et al. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma , 2008, Genes, chromosomes & cancer.
[18] A. Tsalenko,et al. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin‐resistant ovarian cancer cells , 2007, Genes, chromosomes & cancer.
[19] E. Gehan. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.
[20] K. Helou,et al. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. , 2005, Cancer genetics and cytogenetics.
[21] E. Partridge,et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). , 1996, Seminars in oncology.
[22] S. Knuutila,et al. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells , 1997, Genes, chromosomes & cancer.
[23] Jaakko Astola,et al. CGH-Plotter: MATLAB toolbox for CGH-data analysis , 2003, Bioinform..
[24] Wen-Lin Kuo,et al. Specific keynote: genome copy number abnormalities in ovarian cancer. , 2003, Gynecologic oncology.
[25] David I. Smith,et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.
[26] Johan Staaf,et al. Normalization of array-CGH data: influence of copy number imbalances , 2007, BMC Genomics.
[27] György Horvath,et al. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. , 2006, European journal of cancer.
[28] K. Helou,et al. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage , 2004, Genes, chromosomes & cancer.
[29] I. Bairati,et al. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas , 2008, Modern Pathology.
[30] K. Kitada,et al. The complicated copy number alterations in chromosome 7 of a lung cancer cell line is explained by a model based on repeated breakage-fusion-bridge cycles. , 2008, Cancer genetics and cytogenetics.
[31] D. Alberts,et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. , 1996, British Journal of Cancer.
[32] Y. Luqmani. Mechanisms of Drug Resistance in Cancer Chemotherapy , 2005, Medical Principles and Practice.
[33] D. Juric,et al. Regional activation of chromosomal arm 7q with and without gene amplification in taxane‐selected human ovarian cancer cell lines , 2006, Genes, chromosomes & cancer.
[34] J. Ihle,et al. Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. , 1990, Oncogene.
[35] E. Thompson,et al. Evi1 is a survival factor which conveys resistance to both TGFβ- and taxol-mediated cell death via PI3K/AKT , 2006, Oncogene.
[36] M. Botta,et al. Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes , 2007, ChemMedChem.
[37] S. Gruvberger,et al. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data , 2002, Genome Biology.
[38] G. Samimi,et al. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. , 2003, Molecular pharmacology.
[39] G. Nucifora,et al. EVI1 and hematopoietic disorders: history and perspectives. , 2006, Gene.
[40] I. Wistuba,et al. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. , 2000, Cancer genetics and cytogenetics.
[41] Jae Hoon Kim,et al. Analysis of chromosomal changes in serous ovarian carcinoma using high‐resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease , 2007, Genes, chromosomes & cancer.
[42] I. Dikic,et al. Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors , 2002, Nature.
[43] S. Kaye. Reversal of drug resistance in ovarian cancer: where do we go from here? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] T. Goto,et al. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. , 2001, Human cell.
[45] S. Johnson,et al. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.
[46] K. Kitada,et al. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. , 2007, Cancer genetics and cytogenetics.
[47] Wen-Lin Kuo,et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. , 2007, Cancer research.
[48] V. Torri,et al. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. , 1997, Gynecologic oncology.
[49] M. Piccart,et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.
[50] Shu-Kay Ng,et al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. , 2002, Molecular cancer therapeutics.